Radcliffe Capital Management’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Radcliffe Capital Management’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-456,764	Closed	-$4.61M	–	860
2022 Q4	$4.61M	Hold	456,764	–	–	0.15%	214
2022 Q3	$4.53M	Buy	456,764 +50,864	+13%	+$503K	0.11%	312
2022 Q2	$4.02M	Hold	405,900	–	–	0.09%	366
2022 Q1	$4M	Hold	405,900	–	–	0.09%	339
2021 Q4	$3.99M	Hold	405,900	–	–	0.1%	269
2021 Q3	$3.95M	Hold	405,900	–	–	0.12%	242
2021 Q2	$3.92M	Buy	+405,900	New	+$3.94M	0.12%	260

Radcliffe Capital Management's BIOT Position: Q1 2023 in Review

Radcliffe Capital Management sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 456,764 shares — an estimated $4.61M sold.

Radcliffe Capital Management first reported a position in BIOT in Q2 2021 and held it in 7 quarters. The position peaked at $4.61M in Q4 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

Radcliffe Capital Management reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Radcliffe Capital Management sold 456,764 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $4.61M.
Radcliffe Capital Management first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q2 2021 and held it in 7 quarters.
Radcliffe Capital Management's Biotech Acquisition Company Class A Ordinary Shares position peaked at $4.61M in Q4 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on Radcliffe Capital Management's 13F filing for Q1 2023, filed 15 May 2023.